.avif)
.avif)
Agios Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Cambridge, MA, USA
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative medicines for rare diseases, with deep expertise rooted in hematology.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@agios.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2008
Headquarters
Cambridge, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Brian Goff (chief executive officer), Cecilia Jones (Chief Financial Officer), Krishnan Viswanadhan (Chief Strategy and Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Agios Pharmaceuticals?
Agios Pharmaceuticals uses the first.last format on agios.com, so Jane Smith would be jane.smith@agios.com.
What approved medicines does Agios Pharmaceuticals currently market?
Agios Pharmaceuticals markets PYRUKYND (mitapivat) for adults with hemolytic anemia due to pyruvate kinase deficiency, and AQVESME (mitapivat) for adults with thalassemia in the United States. Both are oral pyruvate kinase activators.
How large is Agios Pharmaceuticals in terms of headcount?
Agios Pharmaceuticals currently employs around 656 people, with its headquarters based in Cambridge, MA. You can use Clay to build a targeted contact list from this employee base when planning outreach.
Who leads Agios Pharmaceuticals as chief executive officer?
Brian Goff serves as the chief executive officer of Agios Pharmaceuticals. Cecilia Jones is the Chief Financial Officer and Krishnan Viswanadhan holds the role of Chief Strategy and Operations Officer.
What rare disease areas does Agios Pharmaceuticals focus on beyond PK deficiency?
Beyond pyruvate kinase deficiency, Agios Pharmaceuticals has active programs targeting thalassemia, sickle cell disease, myelodysplastic syndromes, polycythemia vera, and phenylketonuria, spanning both late-stage and early-stage clinical development.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating